Abstract
One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RF, D’Angio G, De Bernardi B, Evans AE, Favrot M and Freeman AI (1988) International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 12: 1874–1881
Finklestein JZ, Krailo MD, Lenarsky C, Ladison S, Blair G, Reynolds CP, Sitarz AL and Hammond GD (1992) 13-Cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Children’s Cancer Study Group. Med Pediatr Oncol 20: 307–311
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhon L, Gu LJ and Wang ZY (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood 72: 567–572
Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE and Peck GL (1988) Prevention of skin cancer in xeroderma pigmentosum with the use of oral Isotretinoin. N Engl J Med 318: 1633–1637
Lippmann SM, Kessler JF and Meyskens FL Jr (1987) Retinoids as preventative and therapeutic anti-cancer agents. Cancer Treat Rep 71: 391–405
Lovat PE, Irving H, Malcolm AJ, Pearson AD and Redfern CP (1997) 9 Cis-retinoic acid – a better retinoid for the modulation of differentiation, proliferation and gene expression in human neuroblastoma. J Neurooncol 31: 85–91
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Garrett M, Brodeur MD, Gerbing RB and Reynolds CP (1999) Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-Cis-retinoic acid. N Eng J Med 341: 1165–1173
Miller WH Jr, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, Gill GM, Truglia JA, Ulm E, Shirley M and Warren RP Jr . (1995) 9-Cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukaemia. Blood 85: 3021–3027
Parmar MKB and Machin D (1995) Survival Analysis: A Practical Approach. John Wiley & Sons: Chichester
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J and Smith PG (1976) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. 1. Introduction and Design. Br J Cancer 34: 585–612
Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, Shurin SB and Seeger RC (1991) Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 366: 203–211
Thiele CJ, Reynolds CP and Israel MA (1985) Decreased expression of N-myc preceded retinoic acid – induced morphological differentiation of human neuroblastoma. Nature 313: 404–406
Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK Ramsay NK and Reynolds CP (1995) Phase 1 trial of 13-Cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13: 894–901
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kohler, J., Imeson, J., Ellershaw, C. et al. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 83, 1124–1127 (2000). https://doi.org/10.1054/bjoc.2000.1425
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1425
Keywords
This article is cited by
-
Immunomodulator polyinosinic-polycytidylic acid enhances the inhibitory effect of 13-cis-retinoic acid on neuroblastoma through a TLR3-related immunogenic-apoptotic response
Laboratory Investigation (2020)
-
Retinoids in Pediatric Onco-Hematology: the Model of Acute Promyelocytic Leukemia and Neuroblastoma
Advances in Therapy (2012)
-
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group
British Journal of Cancer (2007)
-
Markedly improving survival of neuroblastoma: a 30-year analysis of 1,646 patients
Pediatric Surgery International (2007)
-
Neuroblastoma
Clinical and Translational Oncology (2005)